CLINICAL RESEARCH OF INFECTIONS IN TRANSPLANTATION

移植感染的临床研究

• 批准号: 6372721
• 负责人: CARLOS V PAYA
• 金额: $ 3.87万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2002-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6372721
• 关键词: Betaherpesvirinae; Epstein Barr virus; clinical research; homologous transplantation; human subject; medical complication; opportunistic infections

DESCRIPTION: (Adapted from Applicant s Abstract) One major barrier limiting the success of human allotransplantation is the transplantation related infec- tious complications. While significant progress has been made in the last decade in elucidating the pathogenesis and the optimal management of trans- plant infectious complications, a number of infections continue to cause sig- nificant morbidity and mortality in the transplant recipient. The applicant is an active clinical investigator in this field and has identified two major areas in which additional research is required to overcome the impact of these infections. These include addressing the role of the family of beta-herpes viruses (CMV, HHV-6, and HHV-7) and Epstein Barr Virus (EBV) induced post- transplant lymphoproliferative disease (PTLD). This clinical research is a fertile ground for training of future clinician investigators as it conveys multidisciplinary interaction: immunology, diagnostic virology, and transplan- tation medicine. Through this award, the applicant is seeking the support to obtain additional training in specific aspects of clinical research including formal courses in patient-oriented research, interactions with the clinical research unit (GCRC), GMP facilities, and additional training in immunotherapy of chronic viral infections in transplant patients. The applicant is seeking the support to, within a clinical research group, address the two mentioned focused areas in infectious diseases in transplantation and in which future clinician investigators will be formally trained. The specific aims that this application will pursue include: I) Study the clinical relevance of HHV-6 and HHV-7 in organ transplant recipients and their interaction with other opportu- nistic viral infections (CMV, EBV, HBV, and HCV). II) Define the clinical value of EBV viral load for the prevention and management of EBV-PTLD, and test the feasibility of cell-based immune therapy for the prevention and trea- tment of EBVPTLD in EBV naive solid organ transplant recipients. Altogether, this award will allow us to address, through rigorous patient-oriented re- search, two areas of transplant infectious complications, which are limiting success in human transplantation. Moreover, it will facilitate to train a cadre of future clinician investigators who will further advance this impor- tant field of clinical medicine.

描述：（改编自申请人的摘要）一个主要的限制障碍 人类同种异体移植的成功在于移植相关感染 棘手的并发症。虽然去年取得了重大进展 十年来阐明反式的发病机制和最佳管理 植物感染并发症，一些感染继续引起信号 移植受者的发病率和死亡率显着。申请人是 该领域活跃的临床研究者，并确定了两个主要的 需要进行额外研究以克服这些影响的领域 感染。其中包括解决β-疱疹家族的作用 病毒（CMV、HHV-6 和 HHV-7）和 Epstein Barr 病毒 (EBV) 诱导的后 移植淋巴组织增生性疾病（PTLD）。这项临床研究是 为未来临床研究人员的培训提供了肥沃的土壤 多学科互动：免疫学、诊断病毒学和移植 药。 通过该奖项，申请人正在寻求支持 获得临床研究特定方面的额外培训，包括 以患者为中心的研究、与临床的互动的正式课程 研究单位 (GCRC)、GMP 设施以及免疫治疗方面的额外培训 移植患者的慢性病毒感染。申请人正在寻求 在临床研究小组内支持解决上述两个问题 移植传染病的重点领域以及未来的发展方向 临床研究人员将接受正式培训。此次活动的具体目标是 应用程序将追求包括：I) 研究 HHV-6 的临床相关性和 器官移植受者中的 HHV-7 及其与其他机会的相互作用 本质病毒感染（CMV、EBV、HBV 和 HCV）。 II) 定义临床 EBV 病毒载量对于预防和管理 EBV-PTLD 的价值，以及 测试基于细胞的免疫疗法预防和治疗的可行性 EBVPTLD 在 EBV 初次实体器官移植受者中的治疗。共， 该奖项将使我们能够通过严格的以患者为导向的重新解决 搜索，移植感染并发症的两个领域，这限制了 人体移植取得成功。此外，这将有助于培训 未来临床研究人员的骨干队伍将进一步推进这一重要性 临床医学领域。